Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A randomized phase II trial of the AIO working groups breast cancer and quality of life

The treatment of this trial consists of endocrine therapy with or without CDK4/6 inhibitor. All substances are approved in Germany/Europe and, moreover, they are standard of care for patients with metastatic breast cancer. They will be prescribed by the investigator and administrated within their labels and according to clinical routine. For purpose of clarification, no study medication will be provided by the Sponsor. All components are available from several pharmaceutical companies (generic products) as well as in different formulations.

Status: In Rekrutierung

Klinische Settings

Beteiligte

Identifier

Kontakt